1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 3: 
Hemorrhage rates versus pial collateral formation and platelet level*
ParameterRate of Any HemorrhageP Value (Pearson)Rate of Significant HemorrhageP Value (Pearson)
Total26/104 (25.0%)10/104 (9.61%)
Good collaterals13/72 (18.1%).01422/72 (2.78%).0004
Poor collaterals13/32 (40.6%)8/32 (25.0%)
Platelets <200K16/42 (38.1%).01118/42 (19.0%).0072
Platelets >200K10/62 (16.1%)2/62 (3.23 %)
  • * Shows significantly higher rates of any hemorrhage and significant hemorrhage (volume > 25 mL) among patients with poor pial collaterals and platelet levels <200,000/μL.